We are live on
!
Find out more
PA
Perceptive Advisors Portfolio holdings
AUM
$6.66B
1-Year Est. Return
360.84%
This Fund
S&P 500
This Quarter
Est. Return
+13.47%
1 Year Est. Return
+360.84%
3 Year Est. Return
+1,707.27%
5 Year Est. Return
+3,210.42%
10 Year Est. Return
+53,055.89%
AUM
$3.57B
AUM Growth
+$553M
(+18%)
Cap. Flow
+$342M
Cap. Flow
% of AUM
9.57%
Top 10 Holdings %
Top 10 Hldgs %
49.57%
Holding
170
New
38
Increased
32
Reduced
29
Closed
33
Avg Time Held Equity + Options
4.4
quarters
Top 10 Avg Time Held Equity + Options
5.6
quarters
Top 20 Avg Time Held Equity + Options
4.8
quarters
Avg Time Held Equity only
4.7
quarters
Top 10 Avg Time Held Equity only
5.6
quarters
Top 20 Avg Time Held Equity only
4.9
quarters
Top Buys
| Rank | Stock | Value |
|---|---|---|
| 1 |
ALXN
Alexion Pharmaceuticals
ALXN
|
+$104M |
| 2 |
Biohaven Pharmaceutical Holding Company Ltd.
BHVN
|
+$79.7M |
| 3 |
Ascendis Pharma A/S
ASND
|
+$55.2M |
| 4 |
YARW
Yarrow Bioscience
YARW
|
+$54M |
| 5 |
Amicus Therapeutics
FOLD
|
+$32.5M |
Top Sells
| Rank | Stock | Value |
|---|---|---|
| 1 |
AnaptysBio
ANAB
|
+$58.5M |
| 2 |
Neurocrine Biosciences
NBIX
|
+$32.9M |
| 3 |
Intuitive Surgical
ISRG
|
+$25.4M |
| 4 |
AVXS
AveXis, Inc. Common Stock
AVXS
|
+$24.2M |
| 5 |
Zimmer Biomet
ZBH
|
+$24.1M |
Sector Composition
| Rank | Sector | Weight |
|---|---|---|
| 1 | Healthcare | 97.46% |
| 2 | Miscellaneous | 1.79% |
| 3 | Consumer Staples | 0.67% |
| 4 | Consumer Discretionary | 0.06% |
| 5 | Industrials | 0.02% |
| Name | Market Value | Portfolio Weight | Shares or Principal |
Change in Stake | Capital Flow | Held Since | |
|---|---|---|---|---|---|---|---|
76
DELISTED
Molecular Templates, Inc.
MTEM
| $5.79M | 0.16% |
48,276
| – | – |
2017 Q3
2 quarters
|
|
|
FOMX
77
DELISTED
Foamix Pharmaceuticals Ltd. Ordinary Shares
FOMX
| $5.73M | 0.16% |
1,117,324
| – | – |
2016 Q2
7 quarters
|
|
78
Biogen
BIIB
$33.8B
| $5.48M | 0.15% |
+20,000
| New | +$6.21M |
2018 Q1
0 quarters
|
|
|
NVTR
79
DELISTED
Nuvectra Corporation Common Stock
NVTR
| $5.01M | 0.14% |
+384,600
| New | +$3.91M |
2018 Q1
0 quarters
|
|
|
80
Intuitive Surgical
ISRG
$149B
| $4.13M | 0.12% |
30,000
-181,755
| -86% | -$25.4M |
2017 Q2
3 quarters
|
|
|
ACHN
81
DELISTED
Achillion Pharmaceuticals
ACHN
| $3.71M | 0.1% |
1,000,000
| – | – |
2017 Q4
1 quarter
|
|
|
IVC
82
DELISTED
Invacare Corporation
IVC
| $3.48M | 0.1% |
200,000
| – | – |
2017 Q3
2 quarters
|
|
83
DELISTED
Marinus Pharmaceuticals, Inc
MRNS
| $3.47M | 0.1% |
226,933
| – | – |
2017 Q3
2 quarters
|
|
|
ATNX
84
DELISTED
Athenex, Inc. Common Stock
ATNX
| $3.23M | 0.09% |
+9,500
| New | +$3.01M |
2018 Q1
0 quarters
|
|
|
ODT
85
DELISTED
Odonate Therapeutics, Inc. Common Stock
ODT
| $3.18M | 0.09% |
150,000
| – | – |
2017 Q4
1 quarter
|
|
|
ALNA
86
DELISTED
Allena Pharmaceuticals
ALNA
| $2.75M | 0.08% |
250,000
| – | – |
2017 Q4
1 quarter
|
|
87
Arrowhead Research
ARWR
$8.21B
| $2.63M | 0.07% |
+365,445
| New | +$2.25M |
2018 Q1
0 quarters
|
|
|
ADXS
88
DELISTED
Advaxis Inc
ADXS
| $2.54M | 0.07% |
+100,000
| New | +$3.73M |
2018 Q1
0 quarters
|
|
|
AKCA
89
DELISTED
Akcea Therapeutics Inc
AKCA
| $2.49M | 0.07% |
+97,144
| New | +$2.09M |
2018 Q1
0 quarters
|
|
|
SBBP
90
DELISTED
Strongbridge Biopharma plc.
SBBP
| $2.43M | 0.07% |
275,000
| – | – |
2017 Q4
1 quarter
|
|
91
PUT
Incyte
INCY
$22B
| $2.23M | 0.06% |
+100,000
| New | +$9.02M |
2018 Q1
0 quarters
|
|
92
McKesson
MCK
$112B
| $2.11M | 0.06% |
+15,000
| New | +$2.34M |
2018 Q1
0 quarters
|
|
|
FRTX
93
DELISTED
Fresh Tracks Therapeutics, Inc. Common Stock
FRTX
| $1.66M | 0.05% |
3,628
| – | – |
2017 Q4
1 quarter
|
|
94
CALL
Puma Biotechnology
PBYI
$522M
| $1.61M | 0.05% |
200,000
+100,000
| +100% | +$7.49M |
2017 Q4
1 quarter
|
|
|
EIGR
95
DELISTED
Eiger BioPharmaceuticals, Inc.
EIGR
| $1.55M | 0.04% |
5,256
| – | – |
2016 Q1
8 quarters
|
|
96
PUT
State Street SPDR S&P Biotech ETF
XBI
$9.71B
| $1.55M | 0.04% |
900,000
+300,000
| +50% | +$27.4M |
2017 Q4
1 quarter
|
|
97
DELISTED
Intra-Cellular Therapies Inc.
ITCI
| $1.47M | 0.04% |
+70,000
| New | +$1.36M |
2018 Q1
0 quarters
|
|
98
Gyre Therapeutics
GYRE
$711M
| $1.42M | 0.04% |
+7,333
| New | +$1.37M |
2018 Q1
0 quarters
|
|
99
Champions Oncology
CSBR
$68.2M
| $1.33M | 0.04% |
366,973
-19,567
| -5% | -$73K |
2015 Q3
10 quarters
|
|
100
Stellantis
STLA
$12.9B
| $1.27M | 0.04% |
62,000
| – | – |
2015 Q2
11 quarters
|
|
Similar funds
QP
FCBT
RWM
AWA
WHRC
KGA
LSERS
CAG
Perceptive Advisors's Q1 2018 Portfolio in Review
As of Q1 2018, Perceptive Advisors held 170 positions worth $3.57B, up 18% from $3.02B the previous quarter. Its ten largest holdings account for 50% of the portfolio.
Perceptive Advisors deployed $342M of net new capital in Q1 2018, opening 38 new positions and adding to 32 existing holdings. Its largest new stake was Alexion Pharmaceuticals: 873,450 shares worth $97.4M.
By sector, the portfolio is most concentrated in Healthcare at 97% of assets, down from 98% a quarter earlier, followed by Miscellaneous and Consumer Staples.
On the sell side, the largest reduction was AnaptysBio, an estimated $58.5M trimmed.
- Perceptive Advisors's largest Q1 2018 buy was Alexion Pharmaceuticals: 873,450 shares worth $97.4M.
- Perceptive Advisors added most to Biohaven Pharmaceutical Holding Company Ltd. in Q1 2018, an estimated $79.7M increase.
- Perceptive Advisors's biggest Q1 2018 reduction was AnaptysBio, cutting an estimated $58.5M.
- Perceptive Advisors fully exited Zimmer Biomet in Q1 2018, selling an estimated $24.1M.
- Perceptive Advisors's ten largest holdings make up 50% of its $3.57B portfolio in Q1 2018.
- Perceptive Advisors opened 38 new positions and closed 33 in Q1 2018.
- Perceptive Advisors's portfolio value rose 18% quarter-over-quarter to $3.57B.
Based on Perceptive Advisors's 13F filing for Q1 2018, filed 15 May 2018.